NasdaqGS:ILMNLife Sciences
Illumina (ILMN) Valuation Check After MyOme Partnership Fuels Renewed Investor Optimism
Illumina (ILMN) just gave investors a fresh talking point with its new collaboration and investment in MyOme, a move that pushed the stock up as the market reassessed its growth runway.
See our latest analysis for Illumina.
The MyOme deal fits a broader shift in sentiment, with Illumina’s recent collaboration driven gains adding to a strong 90 day share price return of 46.78 percent, even as the five year total shareholder return remains deeply negative and suggests investors are only...